Cecilia C. Low Wang, MD

Medical Safety Officer, CPC Clinical Research

Professor of Medicine

University of Colorado School of Medicine, Department of Medicine

Cecilia C. Low Wang, MD, FACP, is an Endocrinologist and Professor of Medicine at the University of Colorado Anschutz Medical Campus School of Medicine, in the Division of Endocrinology, Metabolism and Diabetes, as well as Lead Clinician-Scientist at CPC Clinical Research, an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. She is the Director of the Glucose Management Team at the University of Colorado Hospital, and Director for Housestaff and Medical Student Education for the Division of Endocrinology.

Dr. Low Wang attended Pomona College and earned her medical degree from the University of Rochester School of Medicine. She completed her internship and residency at the University of Utah Health Sciences Center where she also served as Chief Medical Resident. After housestaff training, she did a clinical and research fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado School of Medicine investigating insulin action in the vascular wall with a focus on vascular smooth muscle cells, and mechanisms of atherosclerosis in diabetes.

After completion of her training she joined the faculty of the Division of Endocrinology, Metabolism and Diabetes at the University of Colorado Anschutz Medical Campus School of Medicine, continuing her clinical work in endocrinology and internal medicine, her basic research in vascular cell biology at the Denver VA Medical Center, and becoming Associate Director for Fellowship/Education for the Division of Endocrinology, Metabolism and Diabetes. She became involved in clinical trials as a panel member of the Colorado Multiple Institutional Review Board. She then joined the Glucose Management Team and the Endocrine and Diabetes Practice at the University of Colorado Hospital, stepping up as Director of the Glucose Management Team, seeing patients in her general endocrine clinic with a focus on diabetes and metabolic disorders, and serving as an inpatient Endocrine consultant.

Currently, Dr. Low Wang’s clinical research interests include risk modification for diabetes and cardiovascular disease, anti-hyperglycemic therapies, glycemic management of hospitalized patients, and diabetic foot ulcer. She serves on an international clinical endpoint adjudication committee with major adverse cardiovascular event, major adverse limb event, and bleeding end points, and has served as Medical Safety Officer for several national trials. Her clinical trials interests include innovative approaches in clinical trials, pharmacovigilance, and the development of novel therapies. She reviews grants, awards and abstracts for the Endocrine Society and reviewer for journals in the diabetes, endocrinology, cardiovascular and hospital medicine fields. Her clinical interests include diabetes, complications of diabetes, insulin resistance, and lifestyle management for metabolic disease.

Dr. Low Wang teaches in a variety of different settings to audiences that include primary care and specialty physicians, advanced practice providers, and trainees (housestaff, medical students, fellows), on topics ranging from endocrine issues in women and diabetes management in a variety of clinical situations, to lipid disorders, obesity, thyroid disorders and osteoporosis. She was selected as a member of the Academy of Medical Educators at the Anschutz Medical Campus, and is a member of the American Diabetes Association and the Endocrine Society. She currently serves the Endocrine Society as a member of the Trainee and Career Development Core Committee and the Clinical Endocrine Update Core Committee. She has previously served on the Strategic Plan Task Force, Research Affairs Core Committee Clinical Research Subcommittee, and the Scientific and Educational Programs Core Committee. She is also a voting member of the Endocrinologic and Metabolic Drugs Advisory Committee for the Food and Drug Administration.